Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and […]
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Part I: US Pharmaceutical Market — Scale, Structural Drivers, and the 2025 Inflection Point Market Size Reality Check: Reconciling Competing
Introduction: The $2 Billion Data Problem Start with the math. A new drug costs roughly $2 billion and a decade
Chemical Databases in Drug Discovery: The Complete IP and R&D Intelligence Playbook Read Post »
The complete guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on extracting maximum asset value from
Off-Label Drugs and Repurposing: The Full IP, Regulatory, and Commercial Playbook Read Post »
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? Read Post »
One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation.
Customer Success: DrugPatentWatch for Your Library Read Post »
How pharma IP teams, portfolio managers, and R&D leads identify, evaluate, and time market entry opportunities across branded, 505(b)(2), and
Biopharmaceutical Market Entry: The Complete IP, ANDA, and 505(b)(2) Playbook Read Post »
EXECUTIVE SUMMARY When a patent expires on the first-in-class drug in a therapeutic area, two things happen simultaneously. The originator’s
Sign in or create a free account to read this DrugPatentWatch article
